U-Care Renal Platform
CE-marked AI-based predictive software, classified as a Class IIb medical device under Regulation (EU) 2017/745 on medical devices (MDR), designed to support AKI management in the ICU.
Artificial Intelligence to support AKI risk management
The U-Care Renal Platform is AI-based predictive software that supports clinicians in assessing the risk of AKI onset or progression in critically ill patients in the ICU.
By automatically processing clinical data, the platform calculates hourly risk estimates for stage 2 or 3 AKI within the next 24 hours and, in patients with stage 2 or 3 AKI, for persistent AKI stage 3.
Press the button to play the video
The modules of our platform
AKIRA
Artificial Intelligence model that predicts the risk of AKI 2/3 occurring within 24 hours
KDIGO BUNDLE – PREVENTION
Automatizes the application of the KDIGO Bundle and drug management in patients AKI 0/1
PERSEA
Artificial Intelligence model that predicts the risk of persistent stage 3 AKI within 96 hours
KDIGO BUNDLE – TREATMENT
Automatizes the application of the KDIGO Bundle and drug management in patients AKI 2/3 and dialysis
Clinical Testimonials
Hear from clinicians using the U-Care Renal Platform in intensive care.
Dr. Carmine Domenico Votta, Intensive Care Unit Clinician at Ospedale Maggiore Lodi.
Dr. Jordi Morillas, Head of the Intensive Care Unit at SCIAS Hospital in Barcelona.
The advantages of our solution
Predictive system enhanced by artificial intelligence
Automated data processing and hourly risk-score updates
Implementation of the KDIGO Guidelines
Use of already available clinical data in hospital routine
Compliance with GDPR and cybersecurity standards
Integration with the ward medical record (FHIR/HL7)
The platform also supports clinicians in medication review by flagging nephrotoxic drugs and doses that may need reassessment based on the patient’s renal function.
By automatically processing clinical data, the platform highlights information relevant to clinical assessment.
Guarantee of quality and reliability
The U-Care Renal Platform is developed in accordance with Regulation (EU) 2017/745 on medical devices (MDR) and is classified as Class IIb medical device software.
In accordance with ISO 13485 certification, development and quality control processes follow specific requirements for medical devices. Furthermore, the processing of personal data is carried out in compliance with the principles and obligations set out in the GDPR.
What could the economic impact be for your healthcare organisation?
According to estimates from the economic impact model, adopting the U-Care Renal Platform may help reduce the costs associated with AKI management in the ICU.
Use our ROI calculator to estimate the potential annual savings for your organisation.